Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

Table 2 Mean changes in PRO measures from baseline to week 24 of the ATLAS study

PRO measure	Placebo (n = 107)	Adalimumab (n = 208)	Overall F value^a	P value^c
BASDAI, 0–10 cm	-1.0 ± 0.23	-2.8 ± 0.17	30.30^b	< 0.001
BASFI, 0–10 cm	-0.5 ± 0.19	-2.0 ± 0.14	23.14^b	< 0.001
SF-36 PCS, 0–50	2.1 ± 0.84	7.3 ± 0.59	24.56^b	< 0.001
SF-36 MCS, 0–50	2.1 ± 0.95	3.7 ± 0.67	42.05^b	0.181
Physical Function	4.1 ± 2.00	13.3 ± 1.42	19.32^b	< 0.001
Role–Physical	10.0 ± 3.51	27.5 ± 2.51	23.00^b	< 0.001
Bodily Pain	7.0 ± 2.03	20.7 ± 1.45	24.39^b	< 0.001
General Health	1.5 ± 1.55	8.7 ± 1.11	21.89^b	< 0.001
Vitality	5.8 ± 1.86	14.6 ± 1.33	21.33^b	< 0.001
Social Function	5.0 ± 2.11	12.6 ± 1.51	34.86^b	0.003
Role–Emotional	5.0 ± 3.55	15.6 ± 2.51	77.42^b	0.015
Mental Health	4.8 ± 1.54	5.9 ± 1.11	30.43^b	0.551
ASQOL, 0–18	-1.1 ± 0.40	-3.5 ± 0.28	17.28^b	< 0.001

Data are least-square mean ± standard error.
^aANCOVA model controlling for baseline score of patient was performed.
^bP < 0.001 based on ANCOVA.
^cP-values based on paired Student t-tests for comparison of means between placebo-treated and adalimumab-treated patients.
ANCOVA = analysis of covariance; ASQOL = AS Quality of Life Questionnaire; ATLAS = Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS; BASDAI = Bath AS Disease Activity Index; BASFI = Bath AS Functional Index; MCS = Mental Component Summary; PCS = Physical Component Summary; PRO = patient-reported outcome; SF-36 = Short Form-36 Health Survey.

ISSN: 1478-6362